JPS6259124B2 - - Google Patents

Info

Publication number
JPS6259124B2
JPS6259124B2 JP54500459A JP50045979A JPS6259124B2 JP S6259124 B2 JPS6259124 B2 JP S6259124B2 JP 54500459 A JP54500459 A JP 54500459A JP 50045979 A JP50045979 A JP 50045979A JP S6259124 B2 JPS6259124 B2 JP S6259124B2
Authority
JP
Japan
Prior art keywords
triazine
organic solvent
activated
resin
nucleophile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP54500459A
Other languages
English (en)
Japanese (ja)
Other versions
JPS55500309A (cg-RX-API-DMAC7.html
Inventor
Reonaado Tee Hotsujinsu
Toomasu Etsuchi Fuinrei
Aran Jei Jonson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
New York University NYU
Original Assignee
New York University NYU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New York University NYU filed Critical New York University NYU
Publication of JPS55500309A publication Critical patent/JPS55500309A/ja
Publication of JPS6259124B2 publication Critical patent/JPS6259124B2/ja
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/10—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a carbohydrate
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/3071—Washing or leaching
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3202—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the carrier, support or substrate used for impregnation or coating
    • B01J20/3206—Organic carriers, supports or substrates
    • B01J20/3208—Polymeric carriers, supports or substrates
    • B01J20/3212—Polymeric carriers, supports or substrates consisting of a polymer obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
    • B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3214—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the method for obtaining this coating or impregnating
    • B01J20/3217—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond
    • B01J20/3219—Resulting in a chemical bond between the coating or impregnating layer and the carrier, support or substrate, e.g. a covalent bond involving a particular spacer or linking group, e.g. for attaching an active group
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244—Non-macromolecular compounds
    • B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244—Non-macromolecular compounds
    • B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
    • B01J20/3251—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising at least two different types of heteroatoms selected from nitrogen, oxygen or sulphur
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244—Non-macromolecular compounds
    • B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
    • B01J20/3253—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising a cyclic structure not containing any of the heteroatoms nitrogen, oxygen or sulfur, e.g. aromatic structures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3244—Non-macromolecular compounds
    • B01J20/3246—Non-macromolecular compounds having a well defined chemical structure
    • B01J20/3248—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such
    • B01J20/3255—Non-macromolecular compounds having a well defined chemical structure the functional group or the linking, spacer or anchoring group as a whole comprising at least one type of heteroatom selected from a nitrogen, oxygen or sulfur, these atoms not being part of the carrier as such comprising a cyclic structure containing at least one of the heteroatoms nitrogen, oxygen or sulfur, e.g. heterocyclic or heteroaromatic structures
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J20/00—Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof
    • B01J20/30—Processes for preparing, regenerating, or reactivating
    • B01J20/32—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating
    • B01J20/3231—Impregnating or coating ; Solid sorbent compositions obtained from processes involving impregnating or coating characterised by the coating or impregnating layer
    • B01J20/3242—Layers with a functional group, e.g. an affinity material, a ligand, a reactant or a complexing group
    • B01J20/3268—Macromolecular compounds
    • B01J20/3272—Polymers obtained by reactions otherwise than involving only carbon to carbon unsaturated bonds
    • B01J20/3274—Proteins, nucleic acids, polysaccharides, antibodies or antigens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0036—Galactans; Derivatives thereof
    • C08B37/0039—Agar; Agarose, i.e. D-galactose, 3,6-anhydro-D-galactose, methylated, sulfated, e.g. from the red algae Gelidium and Gracilaria; Agaropectin; Derivatives thereof, e.g. Sepharose, i.e. crosslinked agarose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/814—Enzyme separation or purification
    • Y10S435/815—Enzyme separation or purification by sorption

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Peptides Or Proteins (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Catalysts (AREA)
JP54500459A 1978-02-09 1979-02-09 Expired JPS6259124B2 (cg-RX-API-DMAC7.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/876,240 US4229537A (en) 1978-02-09 1978-02-09 Preparation of trichloro-s-triazine activated supports for coupling ligands

Publications (2)

Publication Number Publication Date
JPS55500309A JPS55500309A (cg-RX-API-DMAC7.html) 1980-05-29
JPS6259124B2 true JPS6259124B2 (cg-RX-API-DMAC7.html) 1987-12-09

Family

ID=25367253

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54500459A Expired JPS6259124B2 (cg-RX-API-DMAC7.html) 1978-02-09 1979-02-09

Country Status (7)

Country Link
US (1) US4229537A (cg-RX-API-DMAC7.html)
EP (1) EP0012751B1 (cg-RX-API-DMAC7.html)
JP (1) JPS6259124B2 (cg-RX-API-DMAC7.html)
CA (1) CA1124190A (cg-RX-API-DMAC7.html)
DE (1) DE2965887D1 (cg-RX-API-DMAC7.html)
IL (1) IL56604A (cg-RX-API-DMAC7.html)
WO (1) WO1979000609A1 (cg-RX-API-DMAC7.html)

Families Citing this family (255)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4357311A (en) * 1980-10-03 1982-11-02 Warner-Lambert Company Substrate for immunoassay and means of preparing same
YU43849B (en) * 1983-08-09 1989-12-31 Akad Wissenschaften Process for preparing macromolecular substances with chemically active filling substances
US4719176A (en) * 1983-10-31 1988-01-12 Klotz Irving M Enzyme-free diagnostic binding reagents
US4693985A (en) * 1984-08-21 1987-09-15 Pall Corporation Methods of concentrating ligands and active membranes used therefor
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
DE3515586A1 (de) * 1985-04-30 1986-11-06 Boehringer Mannheim Gmbh, 6800 Mannheim Stabilisiertes sarcosinoxidase-praeparat
US4886836A (en) * 1987-06-03 1989-12-12 Pall Corporation Activated medium with low non-specific protein adsorption
US5001048A (en) * 1987-06-05 1991-03-19 Aurthur D. Little, Inc. Electrical biosensor containing a biological receptor immobilized and stabilized in a protein film
US5192507A (en) * 1987-06-05 1993-03-09 Arthur D. Little, Inc. Receptor-based biosensors
US5160626A (en) * 1987-09-14 1992-11-03 Gelman Sciences Inc. Blotting methods using polyaldehyde activated membranes
US4992172A (en) * 1987-09-14 1991-02-12 Gelman Sciences, Inc. Blotting methods using polyaldehyde activated membranes
US4961852A (en) * 1987-09-14 1990-10-09 Gelman Sciences, Inc. Polyaldehyde activated membranes
AU4529289A (en) * 1988-10-17 1990-05-14 Sepracor, Inc. Process for the covalent surface modification of hydrophobic polymers and articles made therefrom
JPH02219571A (ja) * 1989-02-20 1990-09-03 Kanebo Ltd 修飾プロテアーゼ及びその製造法
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
JPH03505222A (ja) * 1989-04-04 1991-11-14 ピットネル　フリッツ 担体にたん白質、ペプチド、補酵素等々を固定化する方法
DE4005927A1 (de) * 1990-02-25 1991-08-29 Roehm Gmbh Immobilisierung von proteinen an traegern
US5133968A (en) * 1990-08-20 1992-07-28 Kanebo, Ltd. Modified protease, method of producing the same and cosmetic products containing the modified protease
US5279955A (en) * 1991-03-01 1994-01-18 Pegg Randall K Heterofunctional crosslinking agent for immobilizing reagents on plastic substrates
US5436147A (en) * 1991-03-01 1995-07-25 Nucleic Assays Corporation Heterobifunctional crosslinked agents for immobilizing molecules on plastic substrates
GB2267502B (en) * 1992-05-28 1997-01-22 Aligena Ag Polymeric reaction products for use in immobilized buffered gels and membranes
IL104734A0 (en) * 1993-02-15 1993-06-10 Univ Bar Ilan Bioactive conjugates of cellulose with amino compounds
JP2871435B2 (ja) * 1993-04-22 1999-03-17 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 親水性ポリマー被覆パーフルオロカーボンポリマーベースのマトリックスの製造方法
ES2227545T3 (es) * 1994-01-11 2005-04-01 Dyax Corporation Proteinas y sus analogos del "dominio de kunitz" inhibidores de calicreina.
US6057287A (en) * 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US6045797A (en) * 1994-03-14 2000-04-04 New York University Medical Center Treatment or diagnosis of diseases or conditions associated with a BLM domain
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5561097A (en) * 1994-04-28 1996-10-01 Minnesota Mining And Manufacturing Company Method of controlling density of ligand coupled onto supports and products produced therefrom
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US5837815A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polypeptide products
US5837524A (en) * 1994-12-15 1998-11-17 Sugen, Inc. PYK2 related polynucleotide products
US5807989A (en) * 1994-12-23 1998-09-15 New York University Methods for treatment or diagnosis of diseases or disorders associated with an APB domain
US6300482B1 (en) * 1995-01-03 2001-10-09 Max-Flanck-Gesellschaft Zuer For{Overscore (D)}Erung Der MDKI, a novel receptor tyrosine kinase
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
JPH11511328A (ja) 1995-09-15 1999-10-05 ベイラー・カレッジ・オブ・メディスン ステロイドレセプター共活性化因子組成物および使用方法
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
WO1997025999A1 (en) 1996-01-16 1997-07-24 Rensselaer Polytechnic Institute Peptides for altering osteoblast adhesion
CA2249206A1 (en) 1996-04-01 1997-10-09 Genentech, Inc. Apo-2li and apo-3 apoptosis polypeptides
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6462176B1 (en) * 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US20040241645A1 (en) * 1997-01-31 2004-12-02 Genentech, Inc. O-fucosyltransferase
ATE356212T1 (de) 1997-01-31 2007-03-15 Genentech Inc O-fukosyltransferase
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
DK1860187T3 (da) * 1997-05-15 2011-10-31 Genentech Inc Apo-2-receptor
EP1003856A1 (en) 1997-06-05 2000-05-31 Board of Regents, The University of Texas System Apaf-1, the ced-4 human homolog, an activator of caspase-3
IL133122A0 (en) * 1997-06-18 2001-03-19 Genentech Inc Apo-2dcr polypeptides
AU8569698A (en) * 1997-07-11 1999-02-08 Brandeis University Method of inducing apoptosis by reducing the level of thiamin
ES2331900T3 (es) * 1997-08-26 2010-01-19 Genentech, Inc. Receptor rtd.
US20030175856A1 (en) * 1997-08-26 2003-09-18 Genetech, Inc. Rtd receptor
US20060141036A1 (en) * 1997-12-12 2006-06-29 Andrx Labs Llc HMG-CoA reductase inhibitor extended release formulation
DE69939732D1 (de) 1998-01-15 2008-11-27 Genentech Inc Apo-2 ligand
ES2331901T3 (es) * 1998-06-12 2010-01-19 Genentech, Inc. Anticuerpos monoclonales, anticuerpos que reaccionan de forma cruzada y procedimiento para la produccion de los mismos.
US6984719B1 (en) 1998-09-17 2006-01-10 Hospital Sainte-Justine Peptide antagonists of prostaglandin F2α receptor
US6368793B1 (en) * 1998-10-14 2002-04-09 Microgenomics, Inc. Metabolic selection methods
ME00238B (me) * 1998-10-23 2011-02-10 Kirin Amgen Inc Mimičko vezivanje dimernog trombopoitetinskog peptida za mp1 receptor sa trombopoietičkom aktivnošću
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6982153B1 (en) 1998-12-03 2006-01-03 Targanta Therapeutics, Inc. DNA sequences from staphylococcus aureus bacteriophage 77 that encode anti-microbial polypeptides
US6861442B1 (en) * 1998-12-30 2005-03-01 Sugen, Inc. PYK2 and inflammation
GB9910807D0 (en) * 1999-05-10 1999-07-07 Prometic Biosciences Limited Novel detoxification agents and their use
CN1370238A (zh) * 1999-06-16 2002-09-18 艾科斯有限公司 人聚(adp－核酸)聚合酶2的物质和方法
US20040235749A1 (en) * 1999-09-15 2004-11-25 Sylvain Chemtob G-protein coupled receptor antagonists
US20030138771A1 (en) * 1999-09-30 2003-07-24 Jerry Pelletier DNA sequences from S. pneumoniae bacteriophage DP1 that encode anti-microbal polypeptides
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
WO2001036972A2 (en) 1999-11-16 2001-05-25 Genentech, Inc. Elisa for vegf
FR2803926B1 (fr) * 2000-01-14 2002-04-05 Thomson Csf Sextant Procede de generation automatique de table de symboles d'un calculateur temps reel
JP4541490B2 (ja) * 2000-04-07 2010-09-08 株式会社カネカ 拡張型心筋症用吸着体
MXPA02010324A (es) 2000-04-21 2003-04-25 Amgen Inc Derivados de peptidos apo-ai/aii.
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6677136B2 (en) 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
WO2002013861A2 (en) * 2000-08-11 2002-02-21 Favrille, Inc. Method and composition for altering a t cell mediated pathology
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
MXPA03010210A (es) 2001-05-11 2004-03-10 Amgen Inc Peptidos y moleculas relacionadas que se enlazan a tall-1.
US7332474B2 (en) * 2001-10-11 2008-02-19 Amgen Inc. Peptides and related compounds having thrombopoietic activity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US20040054082A1 (en) * 2001-12-03 2004-03-18 Bank David H Toughened polymer blends with improved surface properties
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
DE60333758D1 (de) 2002-06-07 2010-09-23 Dyax Corp Prevention und Verringerung von Ischemia
US7521530B2 (en) 2002-06-11 2009-04-21 Universite De Montreal Peptides and peptidomimetics useful for inhibiting the activity of prostaglandin F2α receptor
EP2386310B1 (en) 2002-08-28 2018-11-07 Dyax Corp. Methods for preserving organs and tissues
US6919426B2 (en) 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
US20050043239A1 (en) * 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
TW200526194A (en) * 2003-10-22 2005-08-16 Merz Pharma Gmbh & Co Kgaa The use of 1-aminocyclohexane derivatives to modify deposition of fibrillogenic Aβ peptides in amyloidopathies
WO2005066621A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Surface acoustic wave sensor assemblies
KR20060113747A (ko) * 2003-12-30 2006-11-02 쓰리엠 이노베이티브 프로퍼티즈 컴파니 기질 및 그에 결합된 화합물
US7658994B2 (en) * 2003-12-30 2010-02-09 3M Innovative Properties Company Substrates and compounds bonded thereto
AU2004315032A1 (en) * 2003-12-30 2005-08-18 3M Innovative Properties Company Acousto-mechanical detection systems and methods of use
DE602005027673D1 (de) 2004-03-05 2011-06-09 Vegenics Pty Ltd Materialien und verfahren für wachstumsfaktorbindende konstrukte
AU2005241431A1 (en) * 2004-04-16 2005-11-17 Genentech, Inc. Assay for antibodies
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US7514223B2 (en) * 2004-05-15 2009-04-07 Genentech, Inc. Cross-screening system and methods for detecting a molecule having binding affinity for a target molecule
WO2005117889A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
MX2007000216A (es) * 2004-07-08 2007-03-15 Amgen Inc Peptidos terapeuticos.
GB0416699D0 (en) * 2004-07-27 2004-09-01 Prometic Biosciences Ltd Prion protein ligands and methods of use
WO2006036834A2 (en) 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
EP2290087A3 (en) 2004-12-22 2011-06-15 Genentech, Inc. Methods for producing soluble multi-membrane-spanning proteins
US20080287469A1 (en) * 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
BRPI0611811A2 (pt) * 2005-06-10 2008-12-09 Prometic Biosciences Ltd ligantes de ligaÇço À proteÍna
US7557190B2 (en) 2005-07-08 2009-07-07 Xencor, Inc. Optimized proteins that target Ep-CAM
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007056411A2 (en) * 2005-11-08 2007-05-18 Genentech, Inc. Method of producing pan-specific antibodies
TW200736277A (en) 2005-11-14 2007-10-01 Amgen Inc RANKL antibody-PTH/PTHrP chimeric molecules
US7276480B1 (en) 2005-12-30 2007-10-02 Dyax Corp. Prevention and reduction of blood loss
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
EP2001500A4 (en) * 2006-03-10 2010-07-28 Dyax Corp FORMULATIONS FOR ECALLANTIDE
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
US7981425B2 (en) 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
ATE540681T1 (de) 2006-06-26 2012-01-15 Amgen Inc Verfahren zur behandlung von atherosklerose
JP5502480B2 (ja) 2006-09-18 2014-05-28 コンピュゲン エルティーディー． 生物活性ペプチド及びその使用方法
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
ZA200901518B (en) 2006-10-04 2010-05-26 Genentech Inc Elisa for VEGF
WO2008051383A2 (en) * 2006-10-19 2008-05-02 Amgen Inc. Use of alcohol co-solvents to improve pegylation reaction yields
AU2007343796A1 (en) 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
US20080171344A1 (en) * 2006-12-22 2008-07-17 Kapsner Kenneth P Methods, Kits and Materials for Diagnosing Disease States by Measuring Isoforms or Proforms of Myeloperoxidase
WO2008083279A1 (en) * 2006-12-29 2008-07-10 3M Innovative Properties Company Method of detection of bioanalytes by acousto-mechanical detection systems comprising the addition of liposomes
AU2008262490B2 (en) 2007-05-22 2011-11-17 Amgen Inc. Compositions and methods for producing bioactive fusion proteins
AU2008273813B2 (en) 2007-07-12 2013-06-13 Compugen Ltd. Bioactive peptides and method of using same
MX348799B (es) 2007-07-26 2017-06-29 Amgen Inc Enzimas aciltransferasa de lecitina-colesterol, modificadas.
WO2009029716A1 (en) 2007-08-28 2009-03-05 Ramot At Tel Aviv University Peptides inducing a cd4i conformation in hiv gp120 while retaining vacant cd4 binding site
DK2808343T3 (da) 2007-12-26 2019-08-19 Xencor Inc Fc-varianter med ændret binding til FcRn
US8129341B2 (en) * 2008-08-25 2012-03-06 New York University Methods for treating diabetic wounds
EP2355828B1 (en) 2008-11-13 2018-05-30 Gilead Calistoga LLC Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
JP2013516389A (ja) * 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
EP2411391A1 (en) 2009-03-24 2012-02-01 Gilead Calistoga LLC Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
CA2759724A1 (en) * 2009-04-20 2010-10-28 Calistoga Pharmaceuticals, Inc. Methods of treatment for solid tumors
US8691829B2 (en) 2009-07-21 2014-04-08 Gilead Calistoga Llc Treatment of liver disorders with PI3K inhibitors
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
MX344935B (es) * 2009-10-26 2017-01-11 Genentech Inc Analisis para detectar anticuerpos especificos a anticuerpos anti-ige terapeuticos y su uso en anafilaxis.
HRP20171537T1 (hr) 2009-11-05 2017-12-15 Rhizen Pharmaceuticals S.A. Novi modulatori benzopiran kinaze
SI3459564T1 (sl) * 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
ES2575160T3 (es) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
EP2571878B1 (en) 2010-05-17 2018-10-17 Incozen Therapeutics Pvt. Ltd. Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases
US9254310B2 (en) 2010-06-17 2016-02-09 New York University Therapeutic and cosmetic uses and applications of calreticulin
WO2012030738A2 (en) 2010-08-30 2012-03-08 Beckman Coulter, Inc. Complex phosphoprotein activation profiles
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
US9029502B2 (en) 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
JP2014506257A (ja) 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
HK1198173A1 (en) 2011-03-16 2015-03-13 Amgen Inc. Potent and selective inhibitors of nav1.3 and nav1.7
MX2013012284A (es) 2011-04-29 2013-11-21 Bristol Myers Squibb Co Regimenes de elevacion de dosis del anticuerpo de proteina 10 inducible por interferon gamma (ip-10).
BR112013027774B1 (pt) 2011-05-04 2020-11-17 Rhizen Pharmaceuticals S.A. composto e composição farmacêutica
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
AP2014007588A0 (en) 2011-09-22 2014-04-30 Amgen Inc CD27L antigen binding proteins
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
EA201691327A1 (ru) 2012-03-05 2017-03-31 Джилид Калистога Ллс Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
US20150079100A1 (en) 2012-03-23 2015-03-19 Bristol-Myers Squibb Company Methods of treatments using ctla-4 antibodies
CA2868161A1 (en) 2012-03-28 2013-10-03 Genentech,Inc. Anti-hcmv idiotypic antibodies and uses thereof
MX359888B (es) 2012-03-30 2018-10-15 Rhizen Pharmaceuticals Sa Novedosos compuestos de 3h-imidazo [4,5-b] piridina 3,5-disubstituida y 3h- [1,2,3] triazolo [4,5-b] piridina 3,5-disubstituida como moduladores de c-met proteina cinasas.
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
US20160067347A1 (en) 2012-12-20 2016-03-10 Amgen Inc. Apj receptor agonists and uses thereof
ES2728936T3 (es) 2013-01-25 2019-10-29 Amgen Inc Anticuerpos dirigidos contra CDH19 para melanoma
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US20150369821A1 (en) 2013-02-06 2015-12-24 Pieris Ag Novel lipocalin-mutein assays for measuring hepcidin concentration
CA2901226C (en) 2013-02-18 2020-11-17 Vegenics Pty Limited Vascular endothelial growth factor binding proteins
TW201446792A (zh) 2013-03-12 2014-12-16 Amgen Inc Nav1．7之強效及選擇性抑制劑
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
HUE045859T2 (hu) 2013-03-15 2020-01-28 Amgen Res Munich Gmbh N-terminális ABP-t tartalmazó, egyláncú kötõmolekulák
EP2970446A1 (en) 2013-03-15 2016-01-20 Amgen Research (Munich) GmbH Antibody constructs for influenza m2 and cd3
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
DK2970486T3 (en) 2013-03-15 2018-08-06 Xencor Inc MODULATION OF T-CELLS WITH BISPECIFIC ANTIBODIES AND FC-FUSIONS
DK2970383T3 (da) 2013-03-15 2021-07-05 Univ Texas Fremgangsmåde til behandling af fibrose
LT2951203T (lt) 2013-03-15 2019-09-10 Xencor, Inc. Heterodimeriniai baltymai
EP3456743B1 (en) 2013-05-30 2021-08-18 Kiniksa Pharmaceuticals, Ltd. Oncostatin m receptor antigen binding proteins
EP3042192A4 (en) * 2013-09-04 2017-04-26 Sten Ohlson Weak affinity chromatography
WO2015036956A1 (en) 2013-09-12 2015-03-19 Institut National De La Sante Et De La Recherche Medicale Method for in vitro quantifying allo-antibodies, auto-antibodies and/or therapeutic antibodies
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
NZ718144A (en) 2013-09-13 2022-05-27 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
WO2015038884A2 (en) 2013-09-13 2015-03-19 Genentech, Inc. Compositions and methods for detecting and quantifying host cell protein in cell lines and recombinant polypeptide products
CU24320B1 (es) 2013-10-11 2018-02-08 Berlin Chemie Ag Anticuerpos conjugados contra antígeno linfocitario 75 para el tratamiento del cáncer
KR20160095161A (ko) 2013-12-20 2016-08-10 길리아드 칼리스토가 엘엘씨 포스파티딜이노시톨 3-키나제 억제제의 가공 방법
JP2017500319A (ja) 2013-12-20 2017-01-05 ギリアード カリストガ エルエルシー （ｓ）−２−（１−（９ｈ−プリン−６−イルアミノ）プロピル）−５−フルオロ−３−フェニルキナゾリン−４（３ｈ）−オンの塩酸塩の多形形態
ES2803217T3 (es) 2014-01-17 2021-01-25 Minomic Int Ltd Antígeno de superficie de células de cáncer de próstata para el diagnóstico
EP3653643A1 (en) 2014-02-20 2020-05-20 Allergan, Inc. Complement component c5 antibodies
JP6643244B2 (ja) 2014-02-27 2020-02-12 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 補体因子Ｂｂ抗体
IL295414B1 (en) 2014-03-27 2025-10-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
SG11201607983YA (en) 2014-03-28 2016-10-28 Xencor Inc Bispecific antibodies that bind to cd38 and cd3
EP3674314B8 (en) 2014-06-10 2023-07-12 Amgen Inc. Apelin polypeptides
AU2015274696B2 (en) 2014-06-13 2018-09-27 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
JP6698065B2 (ja) 2014-07-31 2020-05-27 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 組織分布が向上した二重特異性単鎖抗体コンストラクト
JP6749312B2 (ja) 2014-07-31 2020-09-02 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 最適化された種間特異的二重特異性単鎖抗体コンストラクト
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
KR20170122216A (ko) 2015-03-06 2017-11-03 제넨테크, 인크. 초순수화 dsba 및 dsbc와 이를 제조하고 사용하는 방법
WO2016149537A1 (en) 2015-03-17 2016-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bank vole prion protein as a broad-spectrum substrate for rt-quic-based detection and discrimination of prion strains
IL283764B2 (en) 2015-04-10 2024-01-01 Amgen Inc Interleukin-2 muteins for the expansion of t-regulatory cells
SI3283524T1 (sl) 2015-04-17 2023-06-30 Amgen Research (Munich) Gmbh Bispecifični konstrukti protiteles za CDH3 in CD3
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
EP3341415B1 (en) 2015-08-28 2021-03-24 H. Hoffnabb-La Roche Ag Anti-hypusine antibodies and uses thereof
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
TWI797073B (zh) 2016-01-25 2023-04-01 德商安美基研究（慕尼黑）公司 包含雙特異性抗體建構物之醫藥組合物
SG11201805770UA (en) 2016-02-03 2018-08-30 Amgen Res Munich Gmbh BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
UY37105A (es) 2016-02-03 2017-09-29 Amgen Res Munich Gmbh Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
KR20240115933A (ko) 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
BR112018073660A2 (pt) 2016-05-16 2019-02-19 Baxalta Incorporated anticorpos anti-fator ix pádua
US11613586B2 (en) 2016-07-15 2023-03-28 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
WO2018136553A1 (en) 2017-01-18 2018-07-26 Genentech, Inc. Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
UY37726A (es) 2017-05-05 2018-11-30 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
CA3078974A1 (en) 2017-10-12 2019-04-18 Immunowake Inc. Vegfr-antibody light chain fusion protein
KR20250111232A (ko) 2017-12-11 2025-07-22 암젠 인크 이중특이적 항체 생성물의 연속 제조 공정
TW201940518A (zh) 2017-12-29 2019-10-16 美商安進公司 針對ｍｕｃ１７和ｃｄ３之雙特異性抗體構建體
AU2019264364B2 (en) 2018-04-30 2024-06-06 Medimmune Limited Conjugates for targeting and clearing aggregates
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CA3104386A1 (en) 2018-07-02 2020-01-09 Amgen Inc. Anti-steap1 antigen-binding protein
MA53325A (fr) 2018-07-30 2021-06-09 Amgen Inc Administration prolongée d'une construction d'anticorps bispécifique se liant à cd33 et cd3
WO2020077212A1 (en) 2018-10-11 2020-04-16 Amgen Inc. Downstream processing of bispecific antibody constructs
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
JP2022537650A (ja) 2019-06-13 2022-08-29 アムジエン・インコーポレーテツド 生物製剤の製造における自動化された生物量に基づく灌流制御
CR20220111A (es) 2019-08-13 2022-05-04 Amgen Inc Muteínas de interleucina-2 para la expansión de células t reguladoras referencia cruzada a solicitudes relacionadas
CA3152946A1 (en) 2019-09-10 2021-03-18 Amgen Inc. Purification method for bispecific antigen-binding polypeptides with enhanced protein l capture dynamic binding capacity
AU2020381536A1 (en) 2019-11-13 2022-04-21 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
MX2022007712A (es) 2019-12-17 2022-09-26 Amgen Inc Agonista doble de interleucina-2/receptor de tnf para uso en terapia.
AU2021263767A1 (en) 2020-04-30 2022-09-08 Genentech, Inc. KRas specific antibodies and uses thereof
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
CA3183693A1 (en) 2020-05-29 2021-12-02 Amgen Inc. Adverse effects-mitigating administration of a bispecific construct binding to cd33 and cd3
KR20230017822A (ko) 2020-06-01 2023-02-06 제넨테크, 인크. 세포외 소포를 만들기 위한 방법 및 이들의 용도
KR20230027270A (ko) 2020-06-23 2023-02-27 지앙수 카니온 파마수티컬 씨오., 엘티디. 항-cd38 항체 및 그의 용도
AU2021308283A1 (en) 2020-07-14 2023-02-02 F. Hoffmann-La Roche Ag Assays for fixed dose combinations
IL302599A (en) 2020-11-06 2023-07-01 Amgen Inc Bispecific molecules bind multi-target antigens of increased selectivity
WO2022212831A1 (en) 2021-04-02 2022-10-06 Amgen Inc. Mageb2 binding constructs
CA3217180A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
IL316597A (en) 2022-05-12 2024-12-01 Amgen Res Munich Gmbh Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
JP2025533434A (ja) 2022-09-14 2025-10-07 アムジエン・インコーポレーテツド 二重特異性分子安定化組成物
WO2024259378A1 (en) 2023-06-14 2024-12-19 Amgen Inc. T cell engager masking molecules

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5252983A (en) * 1975-09-29 1977-04-28 Kyowa Hakko Kogyo Co Ltd Resin compositions for fixing physiologically active substances

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3619371A (en) * 1967-07-03 1971-11-09 Nat Res Dev Production of a polymeric matrix having a biologically active substance bound thereto
US3824150A (en) * 1967-07-14 1974-07-16 Nat Res Dev Enzyme bound to polymeric sheet with a triazine bridging group
US3674767A (en) * 1967-07-14 1972-07-04 Nat Res Dev Novel polymeric materials containing triazinyl groups
SE343210B (cg-RX-API-DMAC7.html) * 1967-12-20 1972-03-06 Pharmacia Ab
US3788945A (en) * 1970-11-09 1974-01-29 Standard Brands Inc Process for isomerizing glucose to fructose
US3876501A (en) * 1973-05-17 1975-04-08 Baxter Laboratories Inc Binding enzymes to activated water-soluble carbohydrates
US4119494A (en) * 1973-08-22 1978-10-10 Rhone-Poulenc Industries Immobilization of enzymes in an anhydrous medium
US4007089A (en) * 1975-04-30 1977-02-08 Nelson Research & Development Company Method for binding biologically active compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5252983A (en) * 1975-09-29 1977-04-28 Kyowa Hakko Kogyo Co Ltd Resin compositions for fixing physiologically active substances

Also Published As

Publication number Publication date
US4229537A (en) 1980-10-21
EP0012751A1 (en) 1980-07-09
CA1124190A (en) 1982-05-25
WO1979000609A1 (en) 1979-08-23
EP0012751A4 (en) 1981-08-27
IL56604A (en) 1982-05-31
JPS55500309A (cg-RX-API-DMAC7.html) 1980-05-29
EP0012751B1 (en) 1983-07-20
IL56604A0 (en) 1979-05-31
DE2965887D1 (en) 1983-08-25

Similar Documents

Publication Publication Date Title
JPS6259124B2 (cg-RX-API-DMAC7.html)
US5092992A (en) Polyethyleneimine matrixes for affinity chromatography
US5153166A (en) Chromatographic stationary supports
US4332694A (en) Three-dimensional carrier of inorganic porous material-reactive polymer and a method for its preparation
US5085779A (en) Polyethyleneimine matrixes for affinity chromatography
JPH06509509A (ja) 活性化支持体材料、それらの調製および使用
JPH01157000A (ja) 凝固因子の単離方法およびそれに適した吸着剤
Carlsson et al. 10 Affinity Chromatography
JP2008169212A (ja) ベンズイミダゾール化合物およびクロマトグラフリガンドとしてのその使用
US4582875A (en) Method of activating hydroxyl groups of a polymeric carrier using 2-fluoro-1-methylpyridinium toluene-4-sulfonate
CN103933947B (zh) 用于清除类风湿因子的血液净化材料及其制备方法
EP0403700B1 (en) Polyethyleneimine matrixes for affinity chromatography
US4562251A (en) Agarose derivatives of amino phenyl boronic acid
JPH02242833A (ja) 多孔性ポリアクリロニトリル組成物、その製法およびその用途
JPH074240B2 (ja) 重合体担体の活性化方法
US4778888A (en) Boron containing 1,3,5-triazines
Turkova Affinity chromatography
CS253971B1 (en) Production method of high active biological effective compounds immobilized on carrier
DK171394B1 (da) Understøtning eller bærer i fast fase, immobiliseret enzym i fast fase på en sådan understøtning, ligandbundet chromatografiaffinitetsmatrix samt fremgangsmåde til adskillelse eller rensning af et stof fra opløsning under anvendelse af understøtningen
JP3583429B2 (ja) 疎水クロマトグラフィーのための分離剤
US4298395A (en) Activated polymeric carriers
KR950004134B1 (ko) 어피니티 크로마토그라피용 폴리에틸렌이민 매트릭스
JPH0553802B2 (cg-RX-API-DMAC7.html)
JPS5917354A (ja) アフイニテイ−クロマトグラフイ−用吸着体
JPS6412280B2 (cg-RX-API-DMAC7.html)